Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02389465 · ClinicalTrials.gov registry record · Phase 4

Stress and Inflammation in Late-Life Depression

A Phase 4 study, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 4
Development phase
119
Enrollment target

NCT02389465: Completed Phase 4 study, sponsored by University of Pennsylvania.

NCT02389465 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 119 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02389465, a Phase 4 study, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 4
Development phase
119 participants
Enrollment target

Study Summary

Over 18% of Americans aged 65 years and older have depression. Recent evidence suggests that there is a link between depression and inflammatory disease. This study investigates the relationship between inflammation in the brain and depression. Comparing biological and psychological differences in depressed and non-depressed people allows researchers to find better ways to treat and prevent depression. All participants will have: neuropsychological tests, an EKG, a spinal tap, a blood draw, and, if depressed, given either an antidepressant coupled with an anti-inflammatory medication or an anti-depressant coupled with a placebo for six weeks. The investigators are trying to correlate brain function with depression levels and biomarkers from the blood and spinal fluid.

Primary Outcome

IL6 levels were measured in participants by blood draw 6 weeks after the first dose was given.

Interventions

  • DRUG Escitalopram + Celecoxib
  • DRUG Escitalopram + Placebo

Trial Details

FieldValue
Enrollment Target 119 participants
Start Date 2014-08
Est. Completion 2022-07-18
Phase Phase 4
University of Pennsylvania

1,423 total trials

What the finished NCT02389465 record still lists

NCT02389465 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower).

The record links to 0 conditions, and to 2 interventions - of which Escitalopram + Celecoxib is the first listed.

NCT02389465 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02389465 about?

NCT02389465 is a clinical study titled "Stress and Inflammation in Late-Life Depression". Over 18% of Americans aged 65 years and older have depression. Recent evidence suggests that there is a link between depression and inflammatory disease. This study investigates the relationship between inflammation in the brain and depression. Comparing biological and psychological differences in d...

What is the current status of trial NCT02389465?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 119 participants. The study started on 2014-08. Estimated completion is 2022-07-18.

What interventions are being tested in trial NCT02389465?

The interventions under investigation include: Escitalopram + Celecoxib (DRUG), Escitalopram + Placebo (DRUG).

Who is sponsoring clinical trial NCT02389465?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02389465's enrollment target sits among peer trials

119 712th of 2000 higher than 1,288 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04870762 · 119 participants · Phase 2

    Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

  • NCT05559853 · 119 participants

    Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

  • NCT06564389 · 119 participants · Phase 1

    FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

  • NCT06742801 · 119 participants · NA

    Onyx™ Liquid Embolic IDE Clinical Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02389465, the US trial registry maintained by the National Library of Medicine. NCT02389465 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.